-
Mashup Score: 7Expanding access to mental health care - 1 month(s) ago
Community Routes: Access to Mental Health Care — a partnership between Teva, Direct Relief and the National Association of Free and Charitable Clinics (NAFC) — is a unique access program that is helping to advance health equity and quality care for underserved populations across the U.S. Teva is providing commonly used medicines that treat depression and anxiety over $17 million as well as $2 million in grant funding over two years to support innovative behavioral health services through local free and
Source: www.tevausa.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. - 2 month(s) ago
This first-to-market launch showcases Teva’s proven strengths in complex generic formulations and enhances Teva’s strategic goal of sustaining a generic powerhouse. O ctreotide acetate for injectable suspension is indicated to treat a cromegaly and severe diarrhea for carcinoid syndrome. PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
#NEWS: Today we are announcing the launch of the first and only generic version of octreotide acetate for injectable suspension in the U.S. Learn more about this treatment and our commitment to ensuring patient access to quality generics: https://t.co/tSGfEJkS3A https://t.co/KtoqnfbwtD
-
-
Mashup Score: 2
Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional data include new Phase 3 RISE and SHINE analyses demonstrating no new or unexpected safety concerns in young adults with schizophrenia treated with UZEDY Global ADVANCE survey findings also reveal real-world experiences and perspectives on long-acting injectable (LAI) schizophrenia treatments from healthcare
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
#NEWS: New data on #schizophrenia treatment with long-acting injectables presented at #PsychCongressElevate2024, underscoring our commitment to meeting the needs of patients. Lean more here: https://t.co/U2MpSpVWhU https://t.co/yrPsysxL3y
-
-
Mashup Score: 5Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook - 7 month(s) ago
Generics business and AUSTEDO ® growth lead Q1 2024 performance. Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023. AUSTEDO – continued growth, up 67% (in the U.S.) from Q1 2023; reaffirming 2024 revenue outlook of ~$1.5 billion. AJOVY ® – revenues of $113 million in Q1 2024, up 18% from Q1 2023. Recent FDA approvals of SIML ANDI ® and
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q1 2024 business results. https://t.co/3ua5I2rb7l Forward-looking statements are subject to the cautionary note included in our Q1 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/KGgOay7hmV
-
-
Mashup Score: 5Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook - 7 month(s) ago
Generics business and AUSTEDO ® growth lead Q1 2024 performance. Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023. AUSTEDO – continued growth, up 67% (in the U.S.) from Q1 2023; reaffirming 2024 revenue outlook of ~$1.5 billion. AJOVY ® – revenues of $113 million in Q1 2024, up 18% from Q1 2023. Recent FDA approvals of SIML ANDI ® and
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q1 2024 business results. https://t.co/3ua5I2rb7l Forward-looking statements are subject to the cautionary note included in our Q1 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/KGgOay7hmV
-
-
Mashup Score: 1
Almost 80% of patients with Huntington’s disease (HD) chorea were able to ach ieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4-week Titration Kit for AUSTEDO AUSTEDO remains the only vesicular monoamine transporter 2 (VMAT2) inhibitor available with 3-year data for this progressive condition 1,2 TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
We are honored to join @AANmember at #AAN2024 to present new data on Huntington's disease (HD). Read about the data here: https://t.co/oCOBoCxoWQ https://t.co/6IXakWmdaX
-
-
Mashup Score: 5
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone microspher es (R064766) Additional UZEDY data include a new analysis from the Phase 3 RISE trial reinforcing its efficacy and safety profile in adults with schizophrenia ADVANCE, a global survey study, will also provide real-world findings on LAI utilization from healthcare professionals, caregivers and patients TEL AVIV, Israel & PARSIPPAN
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
As part of our commitment to innovation in #schizophrenia treatment, we presented our latest research evaluating a long-acting treatment option at the @SIRSGlobal annual meeting. Learn more: https://t.co/eevt4N2MbG #SIRS2024 https://t.co/CCwA9ULa7v
-
-
Mashup Score: 10Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma - 1 year(s) ago
Biolojic’s BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases. Agreement builds on Teva’s Pivot to Growth strategy to step up innovation on Teva’s innovative pipeline. Teva to obtain exclusive worldwide rights to develop and commercialize BD9 multibody for potential treatment for Atopic Dermatitis and Asthma TEL AVIV, Israel–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
Teva and Biolojic announce an exclusive license agreement to develop a therapeutic antibody for atopic dermatitis and asthma. Read our press release here: https://t.co/oJul0Xk58N
-
-
Mashup Score: 1
2023 revenues outlook revised to $15.1 – $15.5 billion from $15.0 – $15.4 billion Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO ®, AJOVY ® and global generics business: Growth of AUSTEDO in North America Growth of AJOVY globally Stable and sustainable generics business in the U.S.; continued growth in Europe and International Markets GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60 Cash flow generated
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q3 2023 business results. https://t.co/A558XW4Ijk Forward-looking statements are subject to the cautionary note included in our Q3 2023 press release. #QuarterlyResults #Earnings $Teva https://t.co/ASzUTnNSgc
-
-
Mashup Score: 1
2023 revenues outlook revised to $15.1 – $15.5 billion from $15.0 – $15.4 billion Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO ®, AJOVY ® and global generics business: Growth of AUSTEDO in North America Growth of AJOVY globally Stable and sustainable generics business in the U.S.; continued growth in Europe and International Markets GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60 Cash flow generated
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q3 2023 business results. https://t.co/A558XW4Ijk Forward-looking statements are subject to the cautionary note included in our Q3 2023 press release. #QuarterlyResults #Earnings $Teva https://t.co/ASzUTnNSgc
-
Big news! Teva, in partnership with @NAFClinics and @DirectRelief, is a winner of the @USCCFoundation Citizens Award. Read more about how our program is helping bring medicines to patients wherever they are. https://t.co/9otAJaNlzg #BusinessSolves #TevaUSA